A 28-day study tested the effectiveness of bromhexine combined with standard care against standard care alone in treating 191 outpatients with mild to moderate COVID-19.
Both treatment groups showed a similar reduction in viral load (measured by specific gene thresholds) over the study period, with no significant differences between them.
Overall, the study concluded that bromhexine did not significantly enhance viral load reduction compared to standard care alone, suggesting it might not be a beneficial antiviral for COVID-19 patients.